Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01586858 · ClinicalTrials.gov registry record
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 67
- Enrollment target
NCT01586858: Clinical Trial study, sponsored by Johns Hopkins University.
NCT01586858 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01586858 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 67 participants
- Enrollment target
Study Summary
Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the long-term safety and efficacy of this drug is not yet clear. This study proposes to follow patients who were enrolled in the RAVE study to determine if treatment with rituximab influences long-term outcomes.
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-05-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01586858
The ClinicalTrials.gov registry entry for NCT01586858 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT01586858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01586858 about?
NCT01586858 is a clinical study titled "Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study". Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the long-term safety and efficacy of thi...
What is the current status of trial NCT01586858?
This trial is currently terminated. The enrollment target is 67 participants. The study started on 2012-05. Estimated completion is 2014-05-15.
What interventions are being tested in trial NCT01586858?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT01586858?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.